Commentary on "A roadmap for the prevention of dementia II. Leon Thal Symposium 2008." Centers of excellence in Alzheimer's disease: It is time to better integrate patient care and clinical research to improve the prevention and treatment of Alzheimer's disease

Alzheimer's and Dementia

Volumn 5, Issue 2, 2009, Pages 133-136

  Doody, Rachelle S ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Alzheimer's disease; Clinical care; Clinical trials; Public policy

Indexed keywords

ALZHEIMER DISEASE; ARTICLE; CHRONIC DISEASE; CLINICAL RESEARCH; DISEASE REGISTRY; DRUG APPROVAL; EARLY DIAGNOSIS; HEALTH CARE DELIVERY; HEALTH CARE POLICY; HIGH RISK POPULATION; HUMAN; INTEGRATIVE MEDICINE; PATIENT CARE; PATIENT PARTICIPATION; PRIORITY JOURNAL; PRODUCT DEVELOPMENT;

EID: 62849091516     PISSN: 15525260     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jalz.2009.01.006     Document Type: Note

References (3)

1. Karlawish J., Cary M.S., Rubright J., and Tenhave T. How redesigning AD clinical trials might increase study partners' willingness to participate. Neurology 71 (2008) 1883-1888
2. Snyder P.J., Papp K.V., Bartkowiak J., Jackson C.E., and Doody R. Recruitment of participants for Alzheimer's disease clinical trials: the role of trust in caregivers, clinical researchers, regulatory authorities, and industry sponsors. Alzheimers Dement 5 (2009) 122-124
3. Doody R. We should not distinguish between symptomatic and disease-modifying treatments in Alzheimer's disease drug development. AD Dement 4 Suppl. 1 (2008) S21-S25